WS #16816
Novo Nordisk reported third-quarter results that significantly exceeded analyst expectations, with EPS of $4.02 and revenue of $12.2 billion. The strong performance underscores the continued demand for its weight-loss and diabetes treatments, providing a bright spot in an otherwise risk-off environment. The stock rose markedly in early trading, offering a defensive anchor for healthcare portfolios amidst the broader tech volatility.
Novo Nordisk Earnings Beat
Novo Nordisk reported third-quarter results that significantly exceeded analyst expectations, with EPS of $4.02 and revenue of $12.2 billion. The strong performance underscores the continued demand for its weight-loss and diabetes treatments, providing a bright spot in an otherwise risk-off environment. The stock rose markedly in early trading, offering a defensive anchor for healthcare portfolios amidst the broader tech volatility.